Chesterford Research Park is delighted to announce Axol’s arrival at the Park. Previously based at Babraham Research Campus, Axol’s move to Chesterford has been necessitated by the organic growth of its business, as a result of the expansion of its product lines and the resulting uptake of its products by customers, making an expansion of its R&D and production facilities necessary.

Axol specialises in the use of stem cell technology to produce highly validated, human cells and critical reagents such as media and growth supplements. The organisation’s expertise includes the reprogramming of cells to induced pluripotent stem cells (iPSCs) and the differentiation of these into various cell types. iPSCs propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, and liver cells) making them a single source of cells that could be used to replace those lost to disease or damage – particularly interesting from a regenerative medicine perspective. The differentiated cells are derived from healthy donors and patients of specific disease backgrounds. As well as working with its own cells, Axol also undertakes reprogramming (where necessary) and differentiation of primary or iPSC cells provided by its pharmaceutical industry customers – thereby freeing up their time to focus on research.

In addition, Axol’s in-house R&D team work to improve existing media, coating solutions and reagents as well as innovate new products for human cell culture, resulting in an expansion of Axol’s product line and the creation of a portfolio of products that will facilitate and enhance the further development of it’s customers life-changing research.

Yichen Shi, Chief Executive Officer, Axol commented of the move: “Chesterford Research Park is ideally positioned to offer us not only the space we need now, but also the opportunity for expansion in the future which is incredibly important for us. We looked at a variety of options but Chesterford stood out due to its location within the cluster, convenient access to major road, rail and air routes and proximity to some of the biggest pharmaceutical players in the industry. We are delighted to be joining the Park community.”

The Science Village at Chesterford Research Park is an ideal HQ for both established and start-up companies which require flexible, high quality and prestigious self-contained accommodation. The innovative, energy efficient building offers individual R&D suites ranging from 1,515 sq ft to 1,993 sq ft, plus excellent flexibility by combining spaces for larger occupation. The fully fitted accommodation - served by high-speed data connectivity and Cat 6 cabling - is also supported by a back up generator. Each suite has demountable benching; two sinks and two fume hoods (with space for a third if required), housed within their own dedicated room.

For further information regarding occupancy options please contact the joint agents for Chesterford Research Park – William Clarke at Savills (01223) 347294 or Michael Jones at Dodson Jones (01223) 358114.


PRESS ENQUIRIES

Sarah Brereton

Limewash

T: 01223 813 557

E: sarah@limewashmedia.com


NOTES TO EDITOR

About Chesterford Research Park

Chesterford Research Park has proven an ideal environment for life science companies to grow and prosper. Leading bioscience names that have located at Chesterford include Illumina Inc, BioFocus and Isogenica. The Park is also home to a number of life science and start-up companies. The attractive 250-acre, low-density development is located close to Cambridge and the M11 with London just one hour away by train from nearby Audley End station, ensuring occupiers and visitors enjoy convenient and easy access. Stansted Airport is just 20 minutes drive away. Chesterford Research Park is being developed by The Churchmanor Estates Company Plc and is owned by Aviva Investors. To find out more, visit www.chesterfordresearchpark.com.

About Axol Bioscience

Axol was co-founded by Jonathan Milner, PhD and Yichen Shi, PhD whose combined expertise and entrepreneurial spirit was the driving force behind the creation of Axol - where innovation, quality and customer service are key. Axol produces highly validated, human cells and critical reagents such as media and growth supplements. The Axol team is passionate about great science, delivering superb customer service and support and innovating future products to help customers advance their research faster. To find out more, visit www.axolbio.com.


Share this Post:
read previous

Axol Bioscience Appoints Chief Business Officer

read next

Specialist stem cell biotech Axol Bioscience enhances its future scientific and commercial endeavours